Emulate Introduces Second Generation Zoë® Culture Module for Replication of Complex Human Biology and Drug Effect | Business
BOSTON – (BUSINESS WIRE) – November 15, 2021–
Emulate, Inc., a leading next generation supplier in vitro models, today launched the Zoë-CM2 ™ Culture Module, a second-generation Zoë instrument that is at the heart of their Human Emulation System ®. Like its predecessor, Zoë-CM2 maintains cell life in Emulate Organ-Chips, automating the precise conditions needed to grow up to 12 chips. With the addition of internet connectivity for remote operation, support and ongoing software updates, Zoë-CM2 now allows researchers to plan their studies remotely, update experimental parameters and extract historical flow and stretch data.
“Zoë-CM2 represents a critical advancement in our human emulation system and its disease research and drug development capabilities,” said Chris Hinojosa, vice president of platform development for Emulate. “By combining cellular sources relevant to humans and the advanced replication of Zoë-CM2’s biological microenvironments, Emulate enables researchers to model complex human biology to uncover new findings in disease pathology and drug effect. This innovation reflects our continued commitment to develop our organ microarray offerings and provide the scientific community with the most recent models for humans. “
Traditional organ-microarray configurations rely on complex, manual syringe pump configurations that not only require high technical expertise, but also result in great variability in experimental success and results. The human emulation system includes microchip instruments, consumables and software designed to make the technology more accessible, easier to use and more reliable so that researchers can generate more reproducible and robust information about human biology. . This complete organ-on-a-chip solution eliminates the need for complex, manual syringe pump installations, and the proprietary technology reduces the risk of bubble formation.
For researchers seeking to reduce the high failure rates of drug development, the human emulation system more accurately predicts the human response to drug candidates by combining human tissues and the advanced replication of the complex biological microenvironment. It has been shown to support organ models with greater cellular complexity and allow better control of the microenvironment, allowing users to create tissue models with in vivo like gene expression. As the human emulation system is an open, organ agnostic platform, it can be used for a myriad of research possibilities and organ models.
When used with the new Zoë Manager web application, academic researchers and drug developers will be able to remotely monitor and update their experiences, as well as streamline technical support. Zoë-CM2’s ongoing software updates will also allow the human emulation system to evolve over time to extend control over the cellular biological microenvironment, thus enabling the development of a new organ and organ model. applications. These future updates will range from improved performance to advanced stretch and flow capabilities for greater experimental flexibility and ease of use.
Zoë-CM2 is available to be shipped in Q4’21; to learn more, visit go.emulatebio.com/zoe.
About Emulate, Inc.
Emulate opens a new era in human health with advanced organ-on-a-chip technology. The Human Emulation System provides a window into the inner workings of human biology and disease – giving researchers innovative technology designed to predict human response with more precision and detail than conventional cell culture or experimental testing on animals. Initiated at Harvard University’s Wyss Institute for Biologically Inspired Engineering and supported by Northpond Ventures, Founders Fund and Perceptive Advisors, Organ-on-a-Chip technology helps researchers in academia, pharmaceuticals and government with its predictive power and its capacity to recreate a human biology faithful to reality. To learn more, visit emulatebio.com or follow us on LinkedIn and Twitter.
View the source version on businesswire.com: https://www.businesswire.com/news/home/202111115005450/en/
CONTACT: Michael Sullivan for Emulate
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: MEDICAL DEVICES GENETIC HEALTH RESEARCH SCIENCE BIOTECHNOLOGY
SOURCE: Emuler, Inc.
Copyright Business Wire 2021.
PUB: 11/15/2021 08: 00 / DISC: 11/15/2021 08:01
Copyright Business Wire 2021.